{ "resourceType" : "Evidence", "id" : "236552", "meta" : { "versionId" : "66", "lastUpdated" : "2025-10-07T17:12:54.639Z", "profile" : ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"] }, "language" : "en", "text" : { "status" : "generated", "div" : "

Generated Narrative: Evidence 236552

version: 66; Last updated: 2025-10-07 17:12:54+0000; Language: en

Profile: ComparativeEvidence

url: https://fevir.net/resources/Evidence/236552

identifier: FEvIR Object Identifier/236552, outcomeId/313880, picoId/85789, sectionId/73212

name: End_stage_kidney_disease_from_MAGICapp_313880

title: MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk

citeAs:

MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236552. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236552. Computable resource at: https://fevir.net/resources/Evidence/236552#json.

\n

status: Active

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication)ComparativeEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

\n

RelatesTos

-TypeTarget[x]
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

\n

assertion:

There is no important difference between GLP-1 receptor agonists and standard care.

\n

variableDefinition

description:

Adults with type 2 diabetes with moderate CV risk

\n

variableRole: Population

observed: Adults with type 2 diabetes and established CVD (but no CKD)

variableDefinition

description:

GroupAssignment: GLP-1 RA vs. Standard care

\n

variableRole: Exposure

comparatorCategory: Standard care

observed: GroupAssignment: GLP-1 RA vs. Standard care

variableDefinition

description:

End-stage kidney disease

\n

variableRole: Outcome

observed: End-stage kidney disease

synthesisType: SYSTEMATIC_REVIEW

studyDesign: randomized assignment

statistic

description:

Risk Difference -0.4% (CI95 -0.7% to -0.2%)

\n

statisticType: risk difference

quantity: -0.004

SampleSizes

-NumberOfStudiesNumberOfParticipants
*410762

AttributeEstimates

-TypeRange
*CI95-0.007--0.002

statistic

description:

OR 0.78 (CI95 0.67 to 0.92)

\n

statisticType: odds ratio

quantity: 0.78

SampleSizes

-NumberOfStudiesNumberOfParticipants
*410762

AttributeEstimates

-TypeRange
*CI950.67-0.92

certainty

type: Overall certainty

rating: High certainty

Subcomponents

-TypeRating
*Risk of BiasNOTSET
*InconsistencyNOTSET
*IndirectnessNOTSET
*ImprecisionNOTSET
*Publication BiasNOTSET
" }, "url" : "https://fevir.net/resources/Evidence/236552", "identifier" : [{ "type" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/v2-0203", "code" : "ACSN", "display" : "Accession ID" }], "text" : "FEvIR Object Identifier" }, "system" : "https://fevir.net/FOI", "value" : "236552", "assigner" : { "display" : "Computable Publishing LLC" } }, { "type" : { "text" : "outcomeId" }, "system" : "https://app.magicapp.org/#/guidelines", "value" : "313880" }, { "type" : { "text" : "picoId" }, "system" : "https://app.magicapp.org/#/guidelines", "value" : "85789" }, { "type" : { "text" : "sectionId" }, "system" : "https://app.magicapp.org/#/guidelines", "value" : "73212" }], "name" : "End_stage_kidney_disease_from_MAGICapp_313880", "title" : "MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk", "citeAs" : "MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236552. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236552. Computable resource at: https://fevir.net/resources/Evidence/236552#json.", "status" : "active", "author" : [{ "name" : "Computable Publishing®: MAGIC-to-FEvIR Converter" }], "publisher" : "Computable Publishing LLC", "contact" : [{ "telecom" : [{ "system" : "email", "value" : "support@computablepublishing.com" }] }], "useContext" : [{ "code" : { "system" : "https://fevir.net/resources/CodeSystem/179423", "code" : "evidence-communication", "display" : "Evidence Communication" }, "valueCodeableConcept" : { "coding" : [{ "system" : "https://fevir.net/resources/CodeSystem/179423", "code" : "ComparativeEvidence", "display" : "ComparativeEvidence" }] } }], "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/", "relatesTo" : [{ "type" : "part-of", "targetReference" : { "type" : "Composition", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "MAGIC-5288-j1Wqrn-conversion-report", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes" } }], "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.", "assertion" : "There is no important difference between GLP-1 receptor agonists and standard care.", "variableDefinition" : [{ "description" : "Adults with type 2 diabetes with moderate CV risk", "variableRole" : "population", "observed" : { "reference" : "Group/236533", "type" : "Group", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "MAGIC-5288-j1Wqrn-population-group-85390-85789", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "Adults with type 2 diabetes and established CVD (but no CKD)" } }, { "description" : "GroupAssignment: GLP-1 RA vs. Standard care", "variableRole" : "exposure", "comparatorCategory" : "Standard care", "observed" : { "reference" : "EvidenceVariable/236536", "type" : "EvidenceVariable", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "MAGIC-5288-j1Wqrn-group-assignment-85390-85789", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "GroupAssignment: GLP-1 RA vs. Standard care" } }, { "description" : "End-stage kidney disease", "variableRole" : "outcome", "observed" : { "reference" : "EvidenceVariable/236551", "type" : "EvidenceVariable", "identifier" : { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "MAGIC-5288-j1Wqrn-313880", "assigner" : { "display" : "Computable Publishing LLC" } }, "display" : "End-stage kidney disease" } }], "synthesisType" : [{ "text" : "SYSTEMATIC_REVIEW" }], "studyDesign" : [{ "coding" : [{ "system" : "http://hl7.org/fhir/study-design", "code" : "SEVCO:01003", "display" : "randomized assignment" }] }], "statistic" : [{ "description" : "Risk Difference -0.4% (CI95 -0.7% to -0.2%)", "statisticType" : { "coding" : [{ "system" : "https://fevir.net/sevco", "code" : "STATO:0000424", "display" : "risk difference" }] }, "quantity" : { "value" : -0.004 }, "sampleSize" : { "numberOfStudies" : 4, "numberOfParticipants" : 10762 }, "attributeEstimate" : [{ "type" : { "text" : "CI95" }, "range" : { "low" : { "value" : -0.007 }, "high" : { "value" : -0.002 } } }] }, { "description" : "OR 0.78 (CI95 0.67 to 0.92)", "statisticType" : { "coding" : [{ "system" : "https://fevir.net/sevco", "code" : "STATO:0000182", "display" : "odds ratio" }] }, "quantity" : { "value" : 0.78 }, "sampleSize" : { "numberOfStudies" : 4, "numberOfParticipants" : 10762 }, "attributeEstimate" : [{ "type" : { "text" : "CI95" }, "range" : { "low" : { "value" : 0.67 }, "high" : { "value" : 0.92 } } }] }], "certainty" : [{ "type" : { "coding" : [{ "system" : "http://hl7.org/fhir/certainty-type", "code" : "Overall", "display" : "Overall certainty" }] }, "rating" : { "coding" : [{ "system" : "https://fevir.net/resources/CodeSystem/27834", "code" : "RJCS-2003", "display" : "High certainty" }] }, "subcomponent" : [{ "type" : { "text" : "Risk of Bias" }, "rating" : { "text" : "NOTSET" } }, { "type" : { "text" : "Inconsistency" }, "rating" : { "text" : "NOTSET" } }, { "type" : { "text" : "Indirectness" }, "rating" : { "text" : "NOTSET" } }, { "type" : { "text" : "Imprecision" }, "rating" : { "text" : "NOTSET" } }, { "type" : { "text" : "Publication Bias" }, "rating" : { "text" : "NOTSET" } }] }] }